Cangrelor
- Generic Name
- Cangrelor
- Brand Names
- Kengreal, Kengrexal
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25Cl2F3N5O12P3S2
- CAS Number
- 163706-06-7
- Unique Ingredient Identifier
- 6AQ1Y404U7
- Background
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic convers...
- Indication
For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
- Associated Conditions
- Coronary Revascularization, Peri-procedural Myocardial Infarction, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Platelet Inhibition to Target Reperfusion Injury
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- National Heart Centre Singapore
- Target Recruit Count
- 228
- Registration Number
- NCT03102723
- Locations
- 🇸🇬
National University Hospital (NUH), Singapore, Singapore
🇸🇬Khoo Teck Puat Hospital, Singapore, Singapore
🇸🇬Changi General Hospital, Singapore, Singapore
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Inova Health Care Services
- Target Recruit Count
- 10
- Registration Number
- NCT03048019
- Locations
- 🇺🇸
Inova Health Care System, Falls Church, Virginia, United States
Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Khaled Ziada, MD
- Target Recruit Count
- 23
- Registration Number
- NCT03043274
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 122
- Registration Number
- NCT02978040
- Locations
- 🇨ðŸ‡
Bern University Hospital, Bern, Switzerland
🇮🇹University of Ferrara, Ferrara, Italy
🇮🇹University of Naples Federico II, Naples, Italy
Cangrelor Neonatal PK/PD and Safety Study
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 22
- Registration Number
- NCT02765633
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
The Effect of IV Cangrelor and Oral Ticagrelor Study
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
- Target Recruit Count
- 100
- Registration Number
- NCT02733341
- Locations
- 🇬🇧
The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
Cangrelor to Clopidogrel or Prasugrel Transition Study
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 15
- Registration Number
- NCT01979445
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Cangrelor Prasugrel Transition Study
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 12
- Registration Number
- NCT01852019
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Cangrelor Ticagrelor Transition Study
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 12
- Registration Number
- NCT01766466
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Maintenance of Platelet Inhibition With Cangrelor
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 221
- Registration Number
- NCT00767507
- Locations
- 🇺🇸
Scripps Clinic / Scripps Green Hospital, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.